Two-year findings from the Vibrance-MG Phase 2/3 long-term extension study showed sustained disease control in adolescents living with anti-AChR+ gMG alongside continued reductions in corticosteroid ...
UCB (Euronext Brussels: UCB), a global biopharmaceutical company, will present a breadth of data from its innovative myasthenia gravis portfolio at the American Association of Neuromuscular & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results